UniCAR02-T-CD123

· AvenCell Europe GmbH

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for UniCAR02-T-CD123, covering 2026-01-22 to 2026-01-22. Get the full timeline:

Most recent: Clinical Trial Update: Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies [Phase 1]